DNMT3A and acute myeloid leukemia: Our study shows that not all DNMT3A mutations are created equal, for example, significantly higher frequency of R882 mutation of all DNMT3A mutations in AML than CHIP (Figure 1) suggests that R882 mutations may confer a higher risk of developing AML than other non-R882 mutations in CHIP.